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Vascular system is constituted by a complex and articulate network, e.g. arteries, arterioles, venules and veins, that requires a high degree of
coordination between different elemental cell types. Proteinase-activated receptors (PARs) constitute a recent described family of 7-
transmembrane G protein-coupled receptors that are activated by proteolysis. In recent years several evidence have been accumulated for an
involvement of this receptor in the response to endothelial injury in vitro and in vivo experimental settings suggesting a role for PAR2 in the
pathophysiology of cardiovascular system.
This review will deal with the role of PAR2 receptor in the cardiovascular system analyzing both in vivo and in vitro published data. In
particular this review will deal with the role of this receptor in vascular reactivity, ischemia/reperfusion injury, coronary atherosclerotic lesions
and angiogenesis.
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Vascular system is constituted by a complex and articulate
network that requires a high degree of coordination between
different elemental cell types. Undoubtedly, the endothelial
cells (EC) play a pivotal role in the vascular homeostasis being
located at the interface between blood and the underlying
smooth muscle cells. EC regulate complex functions compliant
to specific necessities in time and location. Protease-activated
receptor-2 (PAR2) has been shown to be involved in vessel
function. In particular it appears to play a role in pathological
conditions. Thus, PAR2 represents one of the most intriguing
receptor since its physiological and physiopathological activity
in the vasculature is not as yet well defined.
Proteinase-activated receptors (PARs) constitute a recent
described family of 7-transmembrane G protein-coupled
receptors that are activated by proteolysis (MacFarlane et al.,
2001; Hollenberg and Compton, 2002). All PARs share a
unique mechanism of activation where the serine proteases1537-1891/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
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unmask a tethered ligand domain that interacts with receptor in
the extracellular loop II initiating signalling. This process is
irreversible since once cleaved PARs they cannot longer be
used by the cell and are degraded terminating signalling
(Cottrell et al., 2003). Thus far, only four receptors belonging
to this family have been described: PAR1, PAR2, PAR3 and
PAR4 (Hollenberg, 1999). The thrombin receptor PAR1 was the
first PAR to be discovered and cloned (Vu et al., 1991). In
1994, Nystedt identified PAR2 cloning a mouse genomic DNA
encoding a proteolitically activated receptor, similar to PAR1
with a different sequence (Nystedt et al., 1994); successively
PAR3 and PAR4 have been identified (Ishihara et al., 1997;
Kahn et al., 1998). While the ligand of PAR1, PAR3 and PAR4
has been identified in thrombin, the physiological agonist of
PAR2 remains elusive, however trypsin seems to be the major
candidate as PAR2 specific ligand since it cleaves the receptor
within the sequence N34/P48 of its extracellular –NH2
terminus, unmasking the tethered sequence SLIGRLETQ. . .
responsible of the receptor autoactivation. Besides trypsin, it
has been shown that PAR2 can be activated by tryptase (Molino
et al., 1997a,b) and factor Xa (Fox et al., 1997), but it is not
activated by thrombin even at concentrations as high as 100
nM (Cicala, 2002). In absence of proteolysis all PARs, with the3 (2005) 247 – 253
ww
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peptides (PARs-AP) which, mimicking the specific tethered
ligand sequence can activate the receptor without causing
proteolysis (Dery et al., 1998).
2. PAR2 signalling
Although it has been demonstrated a wide tissue distribution
of PAR2, in particular in mammalian tissue (Pearson et al.,
2001), there are not much studies examining PAR2-mediated
intracellular signalling compared to PAR1. An explanation of
this could be imputable to the relative low degree of expression
of PAR2 in basal condition when compared to PAR1. The
involvement of PAR2 activation is well documented much
more in physio-pathological than in physiological environ-
ment. Indeed, a role for PAR2 has been proposed in
proliferative (Mirza et al., 1996; Akers et al., 2000; Frungieri
et al., 2002; Gaca et al., 2002) and inflammatory processes
(Wakita et al., 1997; Cicala et al., 1999; Vergnolle et al., 1999,
2001; Ferrell et al., 2003). A linkage between PAR2, SAP-
kinase, JNK, and P38 MAP kinase has been found in cardiac
myocytes and in transfected skin epithelial cells (Belham et al.,
1996; Sabri et al., 2000), indicating that PAR2 activation can be
involved in proinflammatory responses (MacFarlane et al.,
2001). In addition, it has been also demonstrated that trypsin
and PAR2AP stimulate nuclear factor kB pathway in keratino-
cyte cell line and in coronary smooth muscle cells (Bretsch-
neider et al., 1999; Kanke et al., 2001) further supporting a
direct involvement of PAR2 activation in proinflammatory
cellular signalling (Table 1). It is well established that PAR2
activation by trypsin or PAR2AP induces an increase of
intracellular calcium together with the production of IP3 and
DAG (Nystedt et al., 1995; Santulli et al., 1995). This pathway
acts through activation of PLC isoforms by using Gq/G11
coupled receptor modulating several intracellular targets
(Macfarlane and Plevin, 2003). The increase of intracellular
calcium upon PAR2 stimulation is fast in onset and returns to
baseline levels within 2 min (Kawabata et al., 1999; Laniyonu
and Hollenberg, 1995). This transient calcium response is
typical of PARs receptor (at least PAR1 and PAR2), sinceTable 1
Pathways involved in PAR2 signal transduction






SAPk Gq/G11 Belham et al., 1996;
Sabri et al., 2000JNK
P38MAPk
Human keratinocytes IP3 Gq/G11 Nystedt et al., 1995;
Santulli et al., 1995DAG
[Ca2+]i
Xenopus oocytes [Ca2+]i Go/Gi Schultheiss et al., 1997
Transfected HEK-293 c-fos Go/Gi Yu and Hinkle, 1997;
MacFarlane et al., 2001
Keratinocytes
cell line
NF-kB Bretschneider et al., 1999;
Kanke et al., 2001
Coronary smooth
muscle cellsactivation of other G-protein-coupled receptors, such as a-
adrenoreceptor, give more prolonged responses (Hollenberg
and Compton, 2003). Activation of PAR2 leads also to G0/Gi
dependent transduction mechanism as demonstrated by the
PTX-sensitive calcium modulation in Xenopus oocytes stim-
ulated with trypsin (Schultheiss et al., 1997) and in HEK-293
transfected with PAR2 stimulated with PAR2-AP (Yu and
Hinkle, 1997). The response of HEK-293 transfected with
PAR2 receptor leads to tyrosine phosphorylation of SHP-2, a
tyrosine phosphatase previously observed to play a role in
PAR1 mitogenic signalling (MacFarlane et al., 2001).
Another peculiar characteristic of PAR receptors consists in
a very rapid desensitization coupled to a receptor internaliza-
tion processes (Bohm et al., 1996; De Fea et al., 2000). For
what concerns PAR2 it is known that the receptor is internalised
through clathrin-coated pits to the endosomes followed by
redistribution to lysosomes (Dery et al., 1999). This phenom-
enon seems to be coupled to specific signalling involving
MAPkinase/ERK1, 2 (De Fea et al., 2000). Signal desensiti-
zation and receptor internalization is also controlled by
phosphorylation of the C-terminal domain of the receptor by
kinase C (Ishii et al., 1994; Bohm et al., 1996) or by G-protein-
coupled-receptor kinases (Krupnick and Benovic, 1998). The
phosphorylated receptor can thus interact with h-arrestin and
dynamin more efficiently and in turn cause desensitization/
internalization (Ishii et al., 1994; Bohm et al., 1996).
The presence of a putative N-linked glycosilation site in the
extracellular domain is a common characteristic of all PAR
members so far discovered (Compton, 2003). Glycosilation
shifts hPAR2 molecular weight from 45 kDa up to 60 kDa. At
least one of these N-linked sites appears to be required for
efficient cell surface expression of PAR2 (Compton et al.,
2002). Expression of hPAR2 is only partially inhibited in
HEK293 cells by using tunicamicin, an inhibitor of cellular
glycosilation machinery, suggesting that receptor glycosylation
is important but not essential for PAR2 expression in this
context (Compton et al., 2001). It has been speculated that N-
linked glycosylation, and in particular the sialylation (Kitagawa
and Paulson, 1994), plays a role in tryptase-induced PAR2
activation (Compton et al., 2001). Indeed, differentially
glycosylated PAR2 may be responsible for the failure of
tryptase responses observed in several previous studies
(Molino et al., 1997a,b; Schechter et al., 1998; Huang et al.,
2001).
3. Involvement of PAR2 in vascular homeostasis
PAR2 is widely expressed in several tissues such as kidney,
stomach, pancreas, intestine, bladder, exocrine glands, airway,
bones, epidermis and brain; in particular it is present in
endothelial and epithelial cells, myocytes, fibroblasts, neu-
rons, glial cells and immune cells (for review see MacFarlane
et al., 2001). Northern blot analysis performed on murine
tissues demonstrated receptor transcripts in highly vascular-
ized organs such as kidney, small intestine, and stomach
(Nystedt et al., 1994). In human species immunohistochem-
ical studies provided a tissue-specific cellular localization of
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against a peptide corresponding to the amino terminal
sequence SLIGKVDGTSHVTGKGV of PAR2 (D’Andrea et
al., 1998). Strong immunolabeling was observed in smooth
muscle of vascular and nonvascular origin from a variety of
tissues, in endothelial and epithelial cells independent of
tissue type, in epidermis, throughout the gastrointestinal tract
and, in central nervous system, in astrocytes and neurons
(D’Andrea et al., 1998).
3.1. In vitro pharmacology
Al-Ani and colleagues first described a functional role for
PAR2 on endothelial cells in 1995. They showed that trypsin
and the PAR2 peptide agonist SLIGRL-NH2 induced an
endothelium dependent vasorelaxation in rat aortic rings. The
vasorelaxant effect was reduced by l-NAME, an inhibitor of
nitric oxide (NO) synthases, supporting an involvement of
the l-arginine/NO pathway (Al Ani et al., 1995). Succes-
sively, endothelium NO dependent response following PAR2
activation has been demonstrated in several other blood
vessels such rabbit aorta (Roy et al., 1998), porcine coronary
(Hwa et al., 1996; Hamilton et al., 1998) and basilar arteries
(Sobey and Cocks, 1998; Sobey et al., 1999). Since
inhibitors of the l-Arginine/NO pathway did not abrogate
the vasodilatory response induced by PAR2 it has been
investigated the possible involvement of other mediators. On
this basis it has been proposed endothelin as second
messenger. Indeed, rapid release of nitric oxide induced by
stimulation of aortic rings with PAR2 agonist, SLIGRL-NH2,
was reduced by pre-treatment with BQ-788, an ETB
endothelin receptor-specific antagonist. Consistent with a
role for endothelin-1 receptor activation in PAR2AP-induced
NO release, endothelin-1 levels were increased significantly
after 5 min of treatment of aortic rings with PAR2AP. These
results strongly support an involvement of ET1B receptor in
PAR2 response (Magazine et al., 1996). Similarly, it has been
shown that NO production did not entirely account for
vasorelaxant action of PAR2AP in resistance vessels (Hamil-
ton and Cocks, 2000) such as rat femoral artery, vein
(Emilsson et al., 1997; Roy et al., 1998) and isolated perfused
normal rat kidney (Trottier et al., 2002). In all these cases
PAR2-induced transient vasorelaxation persisted even after
removal of the NO component of PAR2-induced vasodilatation,
by blocking nitric oxide synthase. This evidence has lead to
hypothesize an involvement of endothelium hyperpolarizing
factors (EDHFs) in PAR2-induced vasodilatation. This hypoth-
esis is supported by the finding that afferent arterioles pre-
constricted with elevated concentration of KCl do not relax to
PAR2AP (Trottier et al., 2002). Consistent with this hypothesis,
on mouse second-order mesenteric arterioles, PAR2-induced
vasorelaxation is endothelium-dependent and inhibited by
either 30 mM KCl-precontraction, or pre-treatment with
apamin, charybdotoxin, or their combination. These results
further support a role for endothelium-dependent hyperpolar-
ization factor in PAR2-induced relaxation that could involve
activation of an apamin/charybdotoxin-sensitive potassiumchannels (McGuire et al., 2002). More recently, it has been
shown that in isolated rat gastric artery receptor activating
peptides for both PAR1 and PAR2 produce endothelium-
dependent vasorelaxation. The multiple mechanisms underly-
ing the PAR1 and PAR2-mediated vasodilatation confirm the
involvement of NO, EDHF and prostanoids (Kawabata et al.,
2004). All these evidences indicate that redundant signalling
pathways contribute to the vasodilatory response following
PAR2 activation as it has been underlined by a recent study on
afferent arterioles (Wang et al., 2005). On the other hand, this
redundancy in PAR2 signalling cascade could play a role in
pathological settings such as inflammation or ischemia in
which PAR2 is thought to be activated. Conversely, while
originally it was shown that removal of endothelium caused the
loss of the vasodilatory effect of PAR2 subsequent studies have
shown that depending on the vascular district an effect can be
evidenced. Thus, while PAR2AP fails to cause contraction in
aortic rings without endothelium (Magazine et al., 1996;
Saiffedine et al., 1996; Emilsson et al., 1997) it contracts in
endothelium denuded rabbit aorta (Komuro et al., 1997). In
addition a vasoconstrictory effect PAR2 mediated (but not
PAR1APs) has been shown in vitro on rat pulmonary artery
(Roy et al., 1998) and human umbilical vein (Saiffedine et al.,
1998). These findings have lead to propose that contraction
could be mediated via a receptor distinct from PAR2 through a
release of a diffusible endothelial derived contracting factor
(EDCF) that is different from previously recognized smooth
muscle agonists such as prostanoid metabolites, endothelin,
noradrenaline, angiotensin-II, acetylcholine (Saiffedine et al.,
1998; MacFarlane et al., 2001).
All this in vitro work has been performed in order to define
the physiological role of PAR2 but the picture is rather
confusing, what can be said is that PAR2 activity is mainly
vasodilatory and it looks like to be district dependent.
Studies performed in vitro simulating pathological condi-
tions have suggested a possible protective role for PAR2. A
protective role for PAR2 has also been proposed in
myocardial ischemia/reperfusion (I/R) injury (McLean et
al., 2002). In particular it has been shown a protective
effect, for PAR2 in the coronary vasculature. Indeed, in
isolated and perfused rat heart SLIGRL-NH2 peptide
produced an endothelium-dependent coronary vasodilatation.
Following after I/R injury, PAR2AP-induced vasodilatation
was selectively preserved as opposite to acetylcholine
response. PAR2 response was not mediated by NO or
prostanoids, but involved the release of an EDHF, possibly
a lipoxygenase-derived eicosanoid, and the activation of
vanilloid receptors on sensory C-fibers (McLean et al.,
2002).
3.2. In vivo pharmacology
Intravenous injection of SLIGRL-NH2 or SLIGKV-NH2
causes hypotension in anesthetized rats (Emilsson et al., 1997;
Cicala et al., 1999) and mice (Cheung et al., 1998). The effect
is dose-dependent, and has been shown do not involve central
vasoregulatory systems, heart rate, or the kidneys. Systemic
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induced by PAR2APs further supporting PAR2AP-induced NO
release hypothesis. The relative role played by PAR2 and PAR1
in physiological conditions has been addressed by developing
mice deficient in PAR2 or PAR1. In this key paper, it has been
evaluated mean arterial pressure and heart rate (HR) changes in
response to PAR1 or PAR2 activation in anesthetized wild-
type (WT), PAR1-deficient (PAR-1
/), and PAR2-deficient
(PAR2
/) mice. In WT mice, SLIGRL-NH2, a PAR2 selective
activating peptide, caused hypotension without changing HR
and this response was virtually absent in PAR2
/ mice. In
addition, the hypotensive and bradycardic responses caused
by PAR1AP in WT mice resulted accentuated in PAR2
(/).
These data confirmed the in vivo specificity of PAR1 and PAR2
respective activating peptides, and the distinct hemodynamic
responses mediated by activation of PAR1 or PAR2. Moreover,
the accentuated response to PAR1 activation in PAR2 deficient
mice suggests that a compensatory response and a potential
receptor cross-talk exists (Damiano et al., 1999a).
As opposite to PAR1, the notion that PAR2 is involved in
pathological more than physiological conditions is supported
by recent literature, even if it is not well established if this
receptor has a protective or detrimental role. A role for PAR2 in
endotoxin shock has been suggested. Indeed, anesthetised rats
20 h from lypopolisaccharide treatment display a powerful
increase of the hypotensive response to PAR2AP and trypsin.
Immunohistochemistry showed a preferential and localised
increased expression of PAR2 in aorta and jugular vein
associated to endotoxin shock (Cicala et al., 1999). A role in
blood pressure control in pathological conditions has been also
shown in spontaneously hypertensive rats (SHR). In this strain
basilar artery displays, in vitro, an enhanced vasodilatation to
PAR2AP as opposite to normotensive. In both strains, response
to PAR2AP was abolished by inhibition of NO synthesisHEART
[Ca2+]i (Sabri et al., 2000)
cardiomyocytes coronary artery
protection
i/r injury (Napoli et al., 2000)
baloon catheter injury 
(Damiano at al., 1999b)
myocardial ischemia 
(McLean et al., 2002)
Fig. 1. In vitro and in vivo efindicating that NO-mediated vasodilatation to PAR2 activation
is selectively activated and augmented in SHR. These results
suggest a protective role for PAR2 in the cerebral circulation
during chronic hypertension (Sobey et al., 1999). A protective
role for PAR2 has been shown also in experimental myocardial
ischemia–reperfusion injury. Indeed, PAR2AP infusion causes
a recovery of myocardial function and decrease in oxidation at
reflow coupled to a reduction of the ischemic risk zone and of
creatine kinase release (Napoli et al., 2000). An enhanced
expression of PAR2 has been also shown in human coronary
atherosclerotic lesions implying that PAR2 dependent cellular
trafficking could play a role in regulating signalling to the
vascular injury (Napoli et al., 2004). A role for PAR2 in
proliferation has been also evaluated in rat carotid artery
subjected to balloon-catheter injury. Following the injury there
was a clear increase in damaged or necrotic smooth muscle
cells when compared to normal vessels. In addition, prolifer-
ating adventitial myofibroblasts and the media and neointima
of injured vessels labelled strongly for PAR2 (Damiano et al.,
1999b). These data further suggest a possible protective or
compensatory role for PAR2 in damaged vessels.
In line with this hypothesis it has been shown that in mouse
model of hind limb ischemia PAR2AP and trypsin administra-
tion increased the reparative angiogenic response with an
accelerated hemodynamic recovery and enhanced limb salvage.
These data also are suggestive of a potential angiogenic property
of PAR2 (Milia et al., 2002). Recently, the involvement of PAR2
in angiogenesis has been also demonstrated by Belting and
colleagues (2004). In particular, it has been shown that PAR2
signalling is downstream to tissue factor (TF)-VIIa protease
complex and it is involved in promoting tumour and angiogen-
esis in mice and human ocular tissue (Belting et al., 2004).
Overall these data suggest a possible role for PAR2 as an
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fects of PAR2 activation.
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induced and active when endothelial damage occurs. However,
it must be pointed out that in other context this receptor has
been shown to be pro-inflammatory. Kawabata et al. (1998)
firstly showed that PAR2AP causes inflammation in rat paw
(Kawabata et al., 1998). This original observation was
confirmed in a more complete study by Vergnolle et al.
(1999). In this study pre-treatment of rats with a cycloox-
ygenase inhibitor or a nitric oxide synthase inhibitor had no
effect on the PAR2AP-induced oedema demonstrating that the
PAR2-induced inflammatory response occurred through a
mechanism largely independent of mast cell activation, and
of the production of prostanoids and nitric oxide (Vergnolle et
al., 1999). The same authors, by intravital microscopy, also
showed that topical addition of PAR2AP to rat mesenteric post
capillary venules induced leukocytes rolling and adherence
(Vergnolle et al., 1999). This effect was not affected by pre-
treatment with a mast cell stabilizer or by prior degranulation of
mast cells but was completely inhibited by pre-treatment with a
platelet-activating factor receptor antagonist WEB 2086
(Vergnolle, 1999). These data suggest that PAR2 activation
could contribute to several early events in the inflammatory
reaction, including leukocyte rolling, adherence, and recruit-
ment, by a mechanism dependent on platelet-activating factor
release. Recently it has been demonstrated an important role for
PAR2 in mediating chronic inflammation; in particular, using
an adjuvant monoarthritis model, Ferrell et al. (2003) show that
joint swelling is substantially inhibited in PAR2 deficient mice
(/) with a complete lack of joint damage. Overall these
experimental data identifies in PAR2 a potential novel target for
the management of inflammation (Fig. 1).
4. Concluding remarks
At the present stage of the research no definitive conclu-
sions can be drawn. However PAR2 activation in the
cardiovascular system appears to be a compensatory response
rather than pathological event. Its tight linkage with l-arginine-
NO pathway, demonstrated in several in vitro and in vivo
setting, suggests a possible cross-talk between these systems.
Indeed, in conditions where a vascular damage occurred PAR2
expression has been shown to be enhanced. On the functional
side PAR2 stimulation, in these cases, causes a beneficial effect
rather than a worsening of the disease. Conversely, activation
of this receptor in other context appears to drive inflammation.
These apparently contrasting results could be explained by the
presence of another receptor or subtype of PAR2, as it has been
already proposed. Alternatively, it may be possible that PAR2 is
a receptor context-sensitive that depending upon the organ
involved and/or the pathological conditions could be either
detrimental or beneficial. This hypothesis is supported by the
fact that different signal transduction have been proposed for
this receptor depending on the experimental setting.
In conclusion ‘‘intriguing receptor’’ remains the most
appropriate appellative for PAR2 since its distribution, activa-
tion and signalling cascade are not unique but variable upon the
environment.References
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